CareRx reports third-quarter 2026 results after the market closes on November 4. Investors will be watching to see whether earnings recover after two recent misses while revenue keeps growing.
CareRx Corp. (TSX: CRRX) will report results for the quarter ended September 30, 2026. The earnings calendar lists EPS consensus at C$0.03, while a separate earnings-trends feed shows C$0.04, based on one analyst. Estimates vary, so neither figure is a settled consensus. The trends feed also forecasts revenue of C$96.34 million, up 3.4% from a year earlier. Follow CRRX.TO on the CareRx stock page.
Recent earnings trend
CareRx Corp
CRRX.TO
CRRX.TO
CareRx Corp
WealthAwesomeMarket cap
$213.76M
P/E
8.4x
Div. yield
2.41%
Div. / share
$0.08
52W high
$3.93
52W low
$3.06
1W change
+1.82%
Beta
0.47
Analyst Price Targets
Based on analyst covering CRRX · as of Sep 17, 2026
Wall Street analysts forecast CRRX stock price to rise 53.1% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$5.14
+53.1% Upside
Current Price
C$3.36
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on CRRX's historical volatility
30-Day Vol
20.1%
Annualized
90-Day Vol
23.7%
Annualized
Trend (90d)
+1.3%
Annualized drift
90d Mean
C$3.38
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$3.37 | C$3.14 – C$3.61 |
| 60 trading days | C$3.37 | C$3.06 – C$3.72 |
| 90 trading days | C$3.38 | C$2.99 – C$3.81 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Analyst coverage: 1 analyst(s) cover this name; upcoming EPS consensus is available.
Beat estimates in 1 of the last 4 comparable quarter(s).
| Fiscal period | Report date | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| 2026-09-30 | 2026-11-04 | — | 0.0300 | — |
| 2026-06-30 | 2026-07-29 | 0.0100 | 0.0300 | -66.7% |
| 2026-03-31 | 2026-05-06 | 0.0200 | 0.0700 | -71.4% |
| 2025-12-31 | 2026-03-04 | 0.3700 | 0.0300 | +1133.3% |
| 2025-09-30 | 2025-11-03 | 0.0200 | 0.0300 | -33.3% |
| 2025-06-30 | 2025-07-30 | 0.0100 | 0.0100 | +0.0% |
Investor takeaway: Forecasts point to higher earnings than a year ago, but CareRx’s recent results call for caution. The company reported EPS of C$0.01 against expectations of C$0.03 in June, and C$0.02 against C$0.07 in March. It beat estimates in one of its last four comparable quarters. The November report will show whether revenue growth is translating into stronger earnings per share.
C$0.04 EPS consensus in the trends feed
The trends feed’s C$0.04 EPS estimate is twice the year-ago figure of C$0.02, but it comes from just one analyst. The earnings calendar lists C$0.03. CareRx has beaten estimates in only one of its last four comparable quarters, so the November 4 report will be a test of earnings progress, not a sure thing.
Bull case
The trends feed forecasts revenue of C$96.34 million, up 3.4% from a year earlier, and EPS of C$0.04, compared with C$0.02 a year ago. In its Q2 2026 release, CareRx reported revenue growth of 2.4% to C$93.6 million and adjusted EBITDA of C$8.0 million. The company also said a new national customer is expected to add about 3,000 residents. If revenue growth continues and operating performance holds up, the results could support the view that CareRx is expanding steadily.
Bear case
CareRx missed estimates in three of its last four reported quarters, including the two most recent. The supplied feeds also disagree on EPS consensus: the calendar lists C$0.03, while the trends feed lists C$0.04 based on one analyst. That’s not much to go on for a precise forecast. Revenue growth may not lift earnings if costs or other factors put pressure on results. Investors will want to see how the quarter compares with CareRx’s recent performance, not just the year-over-year growth forecast.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
